Sumitomo Chemical Co earnings date
Sumitomo Chemical Co (SOMMF) Q2 2026 Earnings Report
SOMMF Q2 2026 EPS Results
- Actual EPS
- $0.16
- Consensus EPS
- $0.16
- Beat/Miss
- Missed by -$0.00
- One Year Ago EPS
- $0.17
SOMMF Q2 2026 Revenue Results
- Actual Revenue
- $3.72B
- Expected Revenue
- $3.78B
- Beat/Miss
- Missed by -$65.44M
- YoY Revenue Growth
- +4.45%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 11/02/2026
- Time
- TBA
- Conference Call
- Monday, November 2, 2026
Sumitomo Chemical Co's next earnings date is estimated for February 3, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call was broadly positive: second-quarter profitability exceeded guidance, the balance sheet improved, and full-year core operating income, net income, revenue and dividends were raised, with core operating income expected to reach a new record high. However, the company continues to face delayed overseas crop protection recovery, weak display conditions, lower profit at Sumitomo Pharma, negative free cash flow, high raw material prices and geopolitical uncertainty. The number and magnitude of the stated achievements outweighed the challenges.
For FY '26, sales revenue is JPY 2.490 trillion, up JPY 130 billion from the previous forecast; core operating income is projected to be JPY 270 billion, an upward revision of JPY 55 billion from the previous forecast of JPY 250 billion and expected to reach a new record high; net income attributable to owners of the parent is projected to be JPY 90 billion, an upward revision of JPY 20 billion from JPY 70 billion; the year-end dividend is revised upward to JPY 9 with a JPY 1 increase, and annual dividend is projected to be JPY 17, JPY 1 higher than last projected; the exchange-rate assumption is JPY 150 to $1 for the second half and JPY 157 for the full year, with naphtha at JPY 99,000 per kiloliter for the full year; ICT & Mobility Solutions is revised from JPY 55 billion to JPY 60 billion, Essential & Green Materials from JPY 20 billion to JPY 75 billion, and Sumitomo Pharma from JPY 94 billion to JPY 108 billion, while Agro & Life Solutions is left unchanged and Others reflects certain levels of risks.
- Strong Second-Quarter Profit GrowthCore operating income was JPY 144.5 billion, up JPY 35.8 billion year-on-year, and net income attributable to owners of the parent was JPY 82.9 billion, up JPY 43.2 billion year-on-year. Both exceeded the forecast announced in August, and first-half results were the second highest first-half results on record.
- Revenue and Operating Income IncreasedSales revenue was JPY 1,172.8 billion, up JPY 77.4 billion year-on-year. Operating income was JPY 138.1 billion, up JPY 34.4 billion year-on-year. The increase in core operating income included a JPY 17.5 billion positive price variance and a JPY 22.8 billion positive volume variance, including changes in equity earnings of affiliates.
- Essential & Green Materials Delivered Significant Profit GrowthCore operating income increased by JPY 80.7 billion year-on-year to JPY 62.1 billion. The improvement was driven by inventory valuation gains in Japan and Singapore accompanying higher feedstock and product market prices, as well as improved Petro Rabigh results following the prior-year periodic plant maintenance and improved refining margins.
- Agro & Life Solutions Profit ImprovedCore operating income increased by JPY 9.6 billion year-on-year to JPY 20.8 billion. Crop protection shipments in Japan remained steady, while improved feed additive profit margins offset slow recovery in crop protection product markets outside Japan.
- Semiconductor and Mobility Businesses Supported ICT ResultsAlthough ICT & Mobility Solutions core operating income declined overall, semiconductor processing material shipments and profit increased due to growing semiconductor demand, and shipments of super engineering plastics increased income. Front-end resists and semiconductor chemicals were identified as products performing well, with semiconductor growth expected to be stronger in the second half.
- Balance Sheet StrengthenedInterest-bearing liabilities decreased by JPY 64.1 billion to JPY 1.0874 trillion, while equity increased by JPY 246 billion to JPY 1.4826 trillion. Following net income and Sumitomo Pharma's capital increase through a public offering, the equity ratio improved to 32.1% and the D/E ratio improved significantly to 0.73x.
- Full-Year Core Profit Forecast Raised to a RecordFY 2026 core operating income guidance was raised by JPY 55 billion from JPY 250 billion to JPY 270 billion, which is expected to be a new record high. Net income attributable to owners of the parent guidance was raised by JPY 20 billion from JPY 70 billion to JPY 90 billion.
- Revenue and Dividend Guidance IncreasedFull-year sales revenue guidance was raised by JPY 130 billion to JPY 2.490 trillion. The year-end dividend was increased by JPY 1 to JPY 9, bringing projected annual dividends to JPY 17, which is JPY 1 higher than the previous projection.
- Upward Revisions for Key SegmentsFull-year core operating income guidance for ICT & Mobility Solutions was raised from JPY 55 billion to JPY 60 billion due to increased semiconductor processing material shipments. Essential & Green Materials was raised from JPY 20 billion to JPY 75 billion due to improved Petro Rabigh profit and loss and temporary inventory valuation gains. Sumitomo Pharma was raised from JPY 94 billion to JPY 108 billion due to strong Gemtesa sales.
- Sumitomo Pharma Product Shipments IncreasedShipments increased due to growth in Orgovyx, a treatment for advanced prostate cancer, and Gemtesa, a treatment for overactive bladder. The company also stated that the Takara business succession will be included in the Advanced Medical Solutions segment from the second half, with profit concentrated in the second half.
- Operating Cash Flow ImprovedCash flows from operating activities were an inflow of JPY 66.6 billion, an increase of JPY 8.9 billion year-on-year, mainly due to improved profit.
- Price Revision Discussions UnderwayThe company is consulting with customers and revising prices toward an appropriate level in response to higher feedstock prices and rising fixed costs, including labor costs.
SOMMF Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 03, 2027 | 2026 (Q3) | 0.15- | 0.18 | ― | ― |
| Nov 02, 2026 | 2026 (Q2) | 0.160.16 | 0.17 | -6.07% (-0.01) | |
| Aug 04, 2026 | 2026 (Q1) | 0.090.15 | -0.02 | 994.93% (+0.17) | |
| May 14, 2026 | 2025 (Q4) | -0.12-0.10 | 0.04 | -365.03% (-0.14) | |
| Feb 03, 2026 | 2025 (Q3) | -0.010.18 | 0.13 | 35.69% (+0.05) | |
| Nov 04, 2025 | 2025 (Q2) | 0.150.17 | -0.12 | 242.96% (+0.29) | |
| Aug 01, 2025 | 2025 (Q1) | -0.00-0.02 | 0.09 | -118.51% (-0.11) | |
| May 14, 2025 | 2024 (Q4) | 0.110.04 | -0.77 | 104.95% (+0.81) | |
| Feb 03, 2025 | 2024 (Q3) | 0.090.13 | -0.13 | 204.99% (+0.26) | |
| Oct 30, 2024 | 2024 (Q2) | -0.17-0.12 | -0.17 | 28.46% (+0.05) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


